Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EIK1004 + docetaxel
- Development stage
- Unknown
- Lead developer
- IMPACT Therapeutics
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
EIK1004 + docetaxel is an investigational combination regimen consisting of EIK1004 (previously IMP1707), an oral, highly potent, and selective small-molecule inhibitor of poly(ADP-ribose) polymerase 1 (PARP1), and docetaxel, a semisynthetic taxane chemotherapy. Developed by Eikon Therapeutics in collaboration with IMPACT Therapeutics, EIK1004 is designed to selectively target PARP1 while sparing PARP2 to minimize hematologic toxicities, and is engineered to cross the blood-brain barrier to address central nervous system (CNS) metastases. Docetaxel works by stabilizing microtubule polymers, thereby disrupting mitosis and promoting cell death. The combination is planned to be evaluated in a clinical trial arm of the Phase 1/2 study EIK1004-001 (NCT06907043) for patients with advanced solid tumors, with initial results expected in the second half of 2027.
- Other names
- EIK1004 + docetaxelEIK1004 and docetaxelEIK-1004 and docetaxelEIK 1004 and docetaxelIMP1707 + docetaxelIMP1707 and docetaxelIMP-1707 and docetaxelIMP 1707 and docetaxel
02
Targets
PARP1 (Poly (adp-ribose) polymerase 1)PARP2 (Poly (adp-ribose) polymerase 2)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on EIK1004 + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EIK1004 + docetaxel.